spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Regulatory bottlenecks mean EU clinicians and patients could lose access to medical devices under new rules

ICON plc

ICON to present at The Medtech Conference 2019 on what companies need to know as Europe faces stringent new medical device regulation

European clinicians and their patients could lose access to vital medical devices, including in-vitro diagnostics, due to a lack of agencies able to certify products in time to comply with strict new regulations.

A particular concern is in-vitro diagnostic devices (IVDs), used to perform tests on samples such as blood, urine and tissue. Whereas only about 7 per cent of in vitro diagnostic devices required clinical evidence for approval under existing EU IVD directives (IVDD), 85 per cent will now need it under IVDR, an increase of almost 80 per cent.

All 500,000 existing medical devices currently on the EU market must be recertified under new Medical Device Regulations (MDR). There is significant concern that tight deadlines and the lack of notified bodies (NB) may result in devices not being recertified.

So far, only 2 of 58 existing notified bodies (NBs) have been designated to operate under the European Union’s MDR and zero for IVDR, causing a regulatory bottleneck. With one NB located in the United Kingdom, BSI-UK, its status is uncertain in the face of Brexit; although, they have established an office in the Netherlands (BSI-UK) where Dutch authorities indicate transitioning designation out of the UK should be seamless.

About 80 percent of NBs operating under existing EU medical device directives had applied for MDR by December 2018, but the certification process is complex, and only a handful are anticipated to be designated this year.

An expert from leading clinical research company ICON plc will join a panel discussion ‘MDR/IVDR - What Now?’ at The Medtech Conference (September 23-25) in Boston, where they will discuss the findings of ICON’s a white paper ‘Higher Costs and Bottlenecks’.

The paper outlines steps medical device and in vitro diagnostic developers must address to maintain market share and in the longer term, develop and maintain financially viable product portfolios.

These include:
1. Overcoming the growing shortage of NBs
2. Addressing new clinical data requirements under MDR and IVDR
3. Developing a global market entry strategy to capitalize on opportunities
4. Considering launching new products in the US and other countries
5. Involving top management in compliance efforts

Will you be attending The Medtech Conference 2019 (September 23-25) in Boston?

ICON’s panel discussion session, ‘MDR/IVDR - What Now?, is on September 24 at 3.45 PM ET (Room 156 AB). If you would like to interview an ICON spokesperson, either by phone or at the conference, we will be happy to make arrangements.
phone +353 1 291 2883
email info-clinical@iconplc.com
web www.iconplc.com
email ICON plc, Headquarters, South County Business Park, Leopardstown, Dublin 18, Ireland
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Argonaut Manufacturing Services Set to Expand Drug Product Fill/Finish Capabilities with Significant Capital Investment

Carlsbad, CA, 10th January 2023 - Argonaut Manufacturing Services (‘Argonaut’), a contract manufacturing organization (CMO) serving the life sciences, molecular diagnostics, and biopharma industries, today announced a capital investment led by majority shareholder Telegraph Hill Partners that will be focused on expansion at their Carlsbad, CA, manufacturing facilities.
More info >>


White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement